US 10,744,199 B2Granted

Epstein-Barr virus vaccines

AssigneeThe USA, as represented by the Secretary, Dept. of Health and Human Services

InventorsMasaru Kanekiyo, Gary J. Nabel, Jeffrey Cohen, Wei Bu

Life of this patent

Estimating the term…

Loading patent…

Abstract

Vaccines are provided that elicit neutralizing antibodies to Epstein-Barr virus (EBV). Some vaccines comprise nanoparticles that display envelope proteins from EBV on their surface. The nanoparticles comprise fusion proteins comprising a monomeric subunit of a self-assembly protein, such as ferritin, joined to at least a portion of an EBV envelope protein. The fusion proteins self-assemble to form the envelope protein-displaying nanoparticles. Such vaccines can be used to vaccinate an individual against infection by different types of Epstein-Barr viruses as well as Epstein-Barr viruses that are antigenically divergent from the virus from which the EBV envelope protein was obtained. Also provided are fusion proteins and nucleic acid molecules encoding such proteins.

Claims9

Dependent claims

A nanoparticle comprising a first fusion protein, wherein the first fusion protein comprises a monomeric subunit protein joined to at least one immunogenic portion from a first Epstein-Barr Virus (EBV) envelope protein selected from the group consisting of gp350, gH, gL and gp42,

wherein the monomeric subunit protein is selected from the group consisting of:
a) a monomeric subunit protein comprising at least 25 contiguous amino acids of an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:11, SEQ ID NO:14, SEQ ID NO:17, SEQ ID NO:20, SEQ ID NO:23, SEQ ID NO:26 and SEQ ID NO:29;
and,
b) a monomeric subunit protein comprising an amino acid sequence at least about 80% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:11, SEQ ID NO:14, SEQ ID NO:17, SEQ ID NO:20, SEQ ID NO:23, SEQ ID NO:26 and SEQ ID NO:29;
wherein the first fusion protein self-assembles into a nanoparticle;
and, wherein the nanoparticle displays the at least one immunogenic portion on its surface.

3 more elements

Dependencies are inferred from the claim text.

Facts

Application: 15/028,655Filed 10 Oct 2014 · us provisional application
Priority: 11 Oct 2013
Published: US 2016/0303224 A120 Oct 2016
Granted: 18 Aug 2020
Term ends: Not estimatedThe source records don’t support an estimate.

Classification21 codes

A61K 39/245
Viral antigens: herpetoviridae, e.g. herpes simplex virus
A61K 39/12
Medicinal preparations containing antigens or antibodies: viral antigens
C07K 14/00
Peptides having more than 20 amino acids
C07K 14/005
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof: from viruses